Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Bupivacaine
Drug ID BADD_D00308
Description Bupivacaine is a widely used local anesthetic agent.
Indications and Usage Bupivacaine is indicated for the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures. Bupivacaine is indicated to induce post-surgical analgesia in adults for up to 72 hours following arthroscopic subacromial decompression by administration into the subacromial space under direct arthroscopic visualization.[L31423] Bupivacaine, together with the NSAID [meloxicam], is indicated for the production of postsurgical analgesia in adult patients for up to 72 hours following bunionectomy, open inguinal herniorrhaphy or total knee arthroplasty.[L34100]
Marketing Status approved; investigational
ATC Code N01BB01
DrugBank ID DB00297
KEGG ID D07552
MeSH ID D002045
PubChem ID 2474
TTD Drug ID D0A0FL
NDC Product Code 52945-069; 59014-0053; 65250-133; 51715-660; 57884-0038; 65250-260; 49396-6601; 65250-266; 17381-024; 72640-017; 81371-5040
UNII Y8335394RO
Synonyms Bupivacaine | 1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide | Marcain | Bupivacain Janapharm | Bupivacain-RPR | Bupivacain RPR | Bupivacaina Braun | Carbostesin | Bupivacaine Carbonate | Bupivacaine Hydrochloride | Bupivacaine Monohydrochloride, Monohydrate | Buvacaina | Dolanaest | Sensorcaine | Svedocain Sin Vasoconstr | Marcaine | Bupivacaine Anhydrous
Chemical Information
Molecular Formula C18H28N2O
CAS Registry Number 38396-39-3
SMILES CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Bone cyst15.02.04.026; 16.11.03.001---
Weight bearing difficulty15.03.05.0340.001000%-
Administration site irritation08.02.04.024; 12.07.04.0240.000607%-
Administration site swelling08.02.04.033; 12.07.04.0330.000607%-
Blood loss anaemia01.03.02.018; 24.07.01.088---
Inadequate analgesia08.06.01.040; 12.02.20.0060.001661%-
Normocytic anaemia01.03.02.0220.000179%-
Phrenic nerve paralysis17.01.04.0240.000179%-
Spherocytic anaemia01.06.05.0020.000179%-
Therapeutic product effect decreased08.06.01.0500.007038%-
Therapeutic product effect delayed08.06.01.0510.005394%-
Therapeutic product effect incomplete08.06.01.0520.009735%-
Therapeutic product effect increased08.06.01.053---
Therapeutic product effect prolonged08.06.01.0540.000786%-
Therapeutic product effect variable08.06.01.0550.001822%-
Therapeutic response delayed08.06.01.060---
Therapeutic response shortened08.06.01.0620.001000%-
The 9th Page    First    Pre   9    Total 9 Pages